ALIVE in the News
Studies Advance Knowledge of HIV Impact on Hepatitis C Infection and Genes that may Thwart Hepatitis C Infection, March 2013
Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus (HCV), co-infection with HIV speeds damage and scarring of liver tissue by almost a decade. In a second study of HCV infection, the Johns Hopkins research team participated in the discovery of two genetic mutations that make it more likely that patients’ immune systems can rid the body of HCV. Both studies are described in articles published in the journal Annals of Internal Medicine.
In the Field: What is the secret behind the ALIVE program’s success? [Radio interview; Air date June 24, 2012]
The Johns Hopkins Bloomberg School of Public Health ALIVE program, or AIDS Linked to the Intravenous Experience, is celebrating 25 years of research into HIV and injection drug use. A large part of the program's success can be attributed to a single person known as Bert. In a special field piece, Scott Goldberg chronicles Bert’s amazing journey from a heroin user to valued employee of the ALIVE program who is responsible for tracking down study participants who have missed visits.
Seminal HIV Injection Drug User Study Marks 20th Anniversary, November 2007
Celebrating two decades of research on HIV infection among injection drug users, the AIDS Linked to the IntraVenous Experience (ALIVE) study has become the longest-running investigation of its kind and has made myriad contributions to the study of HIV/AIDS. Based at the Johns Hopkins Bloomberg School of Public Health and conducted in Baltimore, Maryland, ALIVE is an observational cohort study that tracks approximately 3,000 injection drug users. Developed in 1987, the community-based study is funded by grants from the National Institute of Drug Abuse (NIDA).